Eli Lilly利用循环RNA和脂质纳米粒子购买Orna治疗药物,价值高达24亿美元,用于推进体细胞疗法,重点是治疗自发免疫疾病和癌症。 Eli Lilly acquires Orna Therapeutics for up to $2.4 billion to advance in vivo cell therapies using circular RNA and lipid nanoparticles, focusing on treating autoimmune diseases and cancers.

Eli Lilly同意以最多24亿美元的价格购买Orna治疗药物, 以利用循环RNA和脂质纳米粒子推进体细胞疗法。 Eli Lilly has agreed to acquire Orna Therapeutics for up to $2.4 billion in a deal aimed at advancing in vivo cell therapies using circular RNA and lipid nanoparticles. 购买于2026年2月9日公布, 让Lilly有机会使用Orna的领头计划ORN-252, 这是一种CD19针对CAR-T的CAR-T疗法, The acquisition, announced on February 9, 2026, gives Lilly access to Orna’s lead program, ORN-252, a CD19-targeting CAR-T therapy designed to treat B cell-driven autoimmune diseases and cancers by enabling the body to produce therapeutic cells directly. 该平台旨在通过简化治疗交付,克服目前外体外细胞疗法的局限性,例如高成本和复杂程度。 The platform aims to overcome limitations of current ex vivo cell therapies, such as high costs and complexity, by simplifying treatment delivery. 这项协议加强了莉莉对遗传医学和肿瘤学的推动,超越其核心肥胖症药物。 The deal strengthens Lilly’s push into genetic medicine and oncology beyond its core obesity drugs.